Table 3.
Demographic and clinical characteristics of US adults newly recommended to start antihypertensive medications and baseline characteristics of SPRINT and ACCORD-BP participants.
| Characteristic | NHANES Newly classified with hypertension and 10-year ASCVD risk >10% (N = 118) |
SPRINT (N = 9361) |
ACCORD (N = 4733) |
|---|---|---|---|
| Weighted mean (SD) or N (weighted percent) | Mean (SD) or N (percent) | Mean (SD) or N (percent) | |
| Demographic variables | |||
| Age (years) | 63.2 (12.3) | 67.9 (9.4) | 62.7 (6.7) |
| Women | 32 (31) | 3332 (36) | 2258 (48) |
| Race/ethnicity | |||
| White, non-Hispanic | 49 (72) | 5399 (58) | 2781 (59) |
| Black, non-Hispanic | 24 (11) | 2802 (30) | 1127 (24) |
| Hispanic | 34 (12) | 984 (11) | 330 (7) |
| Other | 11 (6) | 176 (2) | 495 (10) |
| Medical history | |||
| Diabetes | 24 (17) | 0 (0) | 4733 (100) |
| CVD | 10 (9) | 1562 (17) | 1593 (34) |
| Atherosclerotic CVD risk (%), mean | 16.9 (7.7) | 22.0 (14.5) | 27.2 (14.5) |
| ASCVD > 10% | 118 (100) | 7602 (81) | 4226 (89) |
| Medications | |||
| Antihypertensive medications | 0 (0) | 8479 (91) | 4132 (87) |
| Lipid-lowering medications | 19 (18) | NA | 3235 (68) |
| Statins | 18 (18) | 4054 (43) | 3063 (65) |
| Fibrates | 0 (0) | NA | 311 (7) |
| Aspirin | 4756 (51) | 2472 (52) | |
| Physical examination | |||
| BMI (kg/m2), mean | 28.5 (7.2) | 29.9 (5.8) | 32.1 (5.5) |
| Systolic BP | 133.1 (4.8) | 139.7 (15.6) | 144.2 (10.5) |
| Diastolic BP | 72.6 (12.3) | 78.1 (11.9) | 78.3 (9.6) |
| Laboratory data | |||
| eGFR (mL/min/1.73 m2), mean | 82.2 (17.8) | 71.7 (20.6) | 91.6 (28.8) |
| eGFR < 60 | 7 (6) | 2650 (28) | 403 (9) |
Cell contents are N, mean (95% CI), or proportion (%) (95% CI). Abbreviations: CVD, cardiovascular disease; ASCVD, atherosclerotic cardiovascular disease; BP, blood pressure; BMI, body mass index; eGFR, estimated glomerular filtration rate.